Trial Participants
vaginal bleeding, endometrial malignant tumors, adenomyosis-associated dysmenorrhea, adenomyosis, menorrhagia
VAGINAL BLEEDING, ENDOMETRIOSIS, UTERINE FIBROIDS, ADENOMYOSIS, MENORRHAGIA, BLOOD, SEVERE ANEMIA
Eligible patients included premenopausal female patients aged between 18 and 50 years with a diagnosis of adenomyosis confirmed by designated ultrasonography or magnetic resonance imaging (MRI) specialists. Patients with adenomyosis-associated dysmenorrhea (visual analog scale [VAS] score >0 points) were included with or without menorrhagia (Pictorial Blood Loss Assessment Chart [PBAC] score ≥100 points). In consideration of the safety of patients in the trial, patients with severe anemia were excluded. The key exclusion criteria were a history of undiagnosed vaginal bleeding outside reference ranges, endometrial malignant tumors, uterine fibroids, or endometriosis. To maintain masking and avoid unwanted pregnancy, patients who did not agree to use nonhormonal contraceptive methods (ie, contraceptive barriers, such as condoms) were excluded. The details are provided in the study protocol (